Samuel L Stanley

US Patent:

52759350, Jan 4, 1994

Filed:

Sep 10, 1992

Appl. No.:

7/943095

Inventors:

Samuel L. Stanley - Ladue MO
Ellen Li - Ladue MO

Assignee:

Washington University - St. Louis MO

International Classification:

G01N 33569
C07K 1528
C12P 2108
C12N 512

US Classification:

435 722

Abstract:

An amebic glycoconjugate is disclosed that is recognized by an Entamoeba histolytica specific monoclonal antibody The glycoconjugate is isolated from the lysates of E. histolytica trophozoites, it is phosphorylated, lipid-containing, glycosylated, migrates as a polydisperse band on SDS-PAGE between about 65-200 kDa and is specifically recognized by monoclonal antibody CC 8. 6, ATCC HB 11104.

US Patent:

58077006, Sep 15, 1998

Filed:

Nov 27, 1995

Appl. No.:

8/562969

Inventors:

Samuel L. Stanley - Ladue MO

Assignee:

Washington University - St. Louis MO

International Classification:

C12Q 118

US Classification:

435 32

Abstract:

There is disclosed an assay method of screening and identification of anti-amebic drugs which utilizes the ability to inhibit anaerobic growth of a novel bacterial mutant that expresses the EhADH2 gene and which bypasses the conventional need for a parasitic culture. The novel mutant, designated E. coli/EhADH2, is cultured under anaerobic conditions, a predetermined or known quantity of the agent to be tested or target compound is combined with the cell culture, and the combination is then monitored to determine the inhibitory effect upon the anaerobic growth of the E. coli/EhADH2 cell mutant.